secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039777
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2
--------------------------------------------------------------------------------

- Cash $1.44B as of June 30, includes $545M net from April public offering.
- Net loss $68.3M for Q2 2023 vs $48.5M in Q2 2022; R&D expenses $72.7M.
- VAX-24 infant Phase 2 advanced to final stage; topline primary data expected by 2025.
- VAX-24 adult Phase 2 positive; Phase 3 topline data expected 2025; VAX-31 IND clearance expected Q4 2023.
- Board member Michael Kamarck passed away in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/0000950170-23-039777-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/pcvx-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039777

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer